Hercules Capital and SVB Provide $75MM Loan Facility to Geron

Hercules Capital and Silicon Valley Bank provided a loan facility of up to $75 million for Geron, supporting the company with access to non-dilutive financial resources to support its imetelstat development program.

October 2, 2020 Geron | Hercules Capital | Imetelstat | Olivia K. Bloom | Silicon Valley Bank Phil Neuffer

SBA Gives ‘Green Light’ for Hercules Capital’s Third SBIC Application

The U.S. Small Business Administration issued a “green light” or “go forth” letter inviting Hercules Capital to finalize its application process to obtain a license to form and operate a third small business investment company subsidiary.

June 8, 2020 Hercules Capital | Scott Bluestein | Small Business Administration Phil Neuffer

Hercules Capital Provides $100MM Credit Facility to G1 Therapeutics

Hercules Capital entered into a $100 million debt financing agreement with G1 Therapeutics, a clinical-stage oncology company. G1 plans to use the proceeds to fund commercialization and further development of trilaciclib.

June 2, 2020 Armentum Partners | Bryan Jadot | G1 Therapeutics | Hercules Capital | Mark Velleca Phil Neuffer

RBC, Umpqua, Others Close $400MM Facility for Hercules Capital

Hercules Capital has replaced its existing $200 million credit facility with MUFG Union Bank with a new $400 million credit facility.

February 20, 2020 FSB | Goldman Sachs | Hercules Capital | MUFG | Royal Bank of Canada | TIAA | Umpqua Bank nadine

Hercules Provides Up to $100MM Facility for ChemoCentryx

ChemoCentryx has secured a credit facility of up to $100 million provided by Hercules Capital.

January 10, 2020 ChemoCentryx | Hercules Capital nadine

Sumitomo Provides $300MM Term Loan to Urovant

Urovant Sciences has entered into a $300 million term loan facility with Sumitomo Dainippon Pharma, a global Japanese pharmaceutical company.

December 31, 2019 Hercules Capital | Sumitomo Dainippon Pharma | Urovant Sciences nadine

Hercules Capital Amends Axovant Facility

Axovant Gene Therapies amended its loan and security agreement with Hercules Capital.

December 3, 2019 Axovant Gene Therapies | Hercules Capital nadine

Hercules Capital Taps Bluestein as President/CEO

Hercules Capital has appointed Scott Bluestein as its chief executive officer and president, effective immediately.

July 18, 2019 Hercules Capital | Scott Bluestein nadine

Hercules Upsizes Antares Pharm Facility to $50MM

Antares Pharma amended its credit facility with Hercules Capital, to increase the available debt capital by $25 million for a term loan of up to $50 million.

June 27, 2019 Antares Pharma | Hercules Capital nadine

Hercules Capital Promotes Jadot, Kuo to Leadership Roles

Hercules Capital promoted R. Bryan Jadot to head of Life Sciences Venture Lending and Steve Kuo to head of Technology Venture Lending.

May 7, 2019 Hercules Capital | R. Bryan Jadot | Steve Kuo nadine